Login to Your Account

Higher Risk, Higher Reward

Algeta Opts for 50-50 Split in Bayer Deal for Alpharadin

By Nuala Moran
Staff Writer

Friday, April 13, 2012
LONDON – Algeta ASA has decided to go for the higher-risk, but hopefully more profitable route in U.S. commercialization of Alpharadin, exercising an option on a 50-50 co-promotion agreement for which it is liable for half the costs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription